What research findings exist regarding Thymosin Alpha-1 in immune regulation and immunoadjuvant therapy?
Tα1 combined with chemotherapy enhances anti-tumor immunity, supporting the miRNA-TLR7 mechanism. Another study reports: immune/chemotherapy regimens containing thymalfasin show results related to survival, immunity, and quality of life.[1] ↗ [2] ↗
Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 2026 · PMID 42295795 | Mouse xenograft and human-derived specimens/cells | Tα1 combined with chemotherapy enhances anti-tumor immunity, supporting the miRNA-TLR7 mechanism. | Human sample does not equal human administration evidence; part of efficacy comes from mice. |
| 2026 · PMID 41994384 | 120 advanced NSCLC patients retrospective combination regimen comparison | Thymoquinone-containing immuno/chemotherapy regimens show outcomes related to survival, immunity, and quality of life. | Background treatments differed between groups and there is no clear isolation of single-drug causality, so it cannot be said that thymoquinone alone prolongs survival. |
| 2026 · PMID 41749205 | Human prospective single-arm; locally advanced gastric/gastroesophageal junction cancer | Immunochemotherapy plus thymalfasin shows pathological response and lymph node clearance development value. | Combined regimen, lacking randomized controls, cannot determine the independent contribution of the thymus method. |
References
What are the anti-tumor immune mechanisms when combined with chemotherapy?
Tα1 combined with chemotherapy enhances anti-tumor immunity, supporting the miRNA-TLR7 mechanism.[1] ↗
Mouse xenograft and human-derived specimens/cells
Human sample does not equal human administration evidence; part of efficacy comes from mice.
View the Article Title and Full Citation＋
Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells.
Cancer research · Volume and issue year 2026
First published 2026-09-01 · PMID 42295795
DOI 10.1158/0008-5472.can-25-5547
What do retrospective data on immunotherapy combination regimens show?
Thymoquinone-containing immuno/chemotherapy regimens show outcomes related to survival, immunity, and quality of life.[2] ↗
120 advanced NSCLC patients retrospective combination regimen comparison
Background treatments differed between groups and there is no clear isolation of single-drug causality, so it cannot be said that thymoquinone alone prolongs survival.
View the Article Title and Full Citation＋
Thymalfasin combined with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: A retrospective study on efficacy, safety, and immunological function.
Pakistan Journal of Medical Sciences · Volume and Issue Year 2026
First published 2026-03-01 · PMID 41994384
DOI 10.12669/pjms.42.3.13385
What has been observed in the combined immunochemotherapy study for stomach cancer?
Immunochemotherapy plus thymalfasin shows pathological response and lymph node clearance development value.[3] ↗
Human prospective single-arm; locally advanced gastric/gastroesophageal junction cancer
Combined regimen, lacking randomized controls, cannot determine the independent contribution of the thymus method.
View the Article Title and Full Citation＋
Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial.
BMC Medicine · Volume and Year 2026
First published 2026-02-26 · PMID 41749205
DOI 10.1186/s12916-026-04740-z
Common issues and corresponding evidence
What research findings exist regarding Thymosin Alpha-1 in immune regulation and immunoadjuvant therapy?＋
Tα1 combined with chemotherapy enhances anti-tumor immunity, supporting the miRNA-TLR7 mechanism. Another study reports: immune/chemotherapy regimens containing thymalfasin show results related to survival, immunity, and quality of life.[1] ↗ [2] ↗
Can the thymosin α1 combination therapy study prove the effectiveness of monotherapy?＋
No. The selected clinical data involve immunotherapy or chemotherapy combination schemes, and animal mechanism studies also have combination conditions; background treatment must be retained, and all benefits cannot be attributed to a single drug.[1] ↗ [2] ↗ [3] ↗
Thymosin Alpha-1—these conclusions apply to which study populations?＋
Mouse xenograft and human-derived specimens/cells; retrospective combined protocol comparison of 120 advanced NSCLC patients; prospective single-arm in humans; locally advanced gastric/gastroesophageal junction cancer. Human samples do not equal evidence of human administration; part of the efficacy is from mice.[1] ↗ [2] ↗ [3] ↗
Thymosin Alpha-1
Return to catalog specifications and batch file verification entry.
